Evidence map›Paper›PMID 34863620›Full record

ArticleVaccine2022

Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.

Helena C Maltezou, Cleo Anastassopoulou, Sophia Hatziantoniou, Gregory A Poland, Athanasios Tsakris

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05648110 (A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants With Conditions Causing Immune Impairment. Sub-study), which is not on this map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05648110 phase2 / phase3completednot on this map

A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants With Conditions Causing Immune Impairment. Sub-study: Phase II Open Label Sub-study to Evaluate the Safety, PK, and Neutralizing Activity of AZD3152 for Pre-exposure Prophylaxis of COVID-19

TypeinterventionalSponsorAstraZenecaRan2022 to 2025Enrolled3,882ConditionsCOVID-19, SARS-CoV-2ArmsAZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort)
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 61 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Cutaneous reactions to vaccination.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Observational
  11. COVID-19 vaccines in 2023.Australian prescriber · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. The conundrum of COVID-19 mRNA vaccine-induced anaphylaxis.The journal of allergy and clinical immunology. Global · 2023
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Helena C MaltezouDirectorate of Research, Studies and Documentation, National Public Health Organization, Athens, Greece. Electronic address: maltezou.helena@gmail.com.
Cleo AnastassopoulouDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Sophia HatziantoniouLaboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, Patras, Greece.
Gregory A PolandMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States.
Athanasios TsakrisDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GRMayo Clinic in Florida · USNational Public Health Organization · GRUniversity of Patras · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We retrieved data on 8940 anaphylaxis cases post-COVID-19 vaccination from the US Vaccine Adverse Event Reporting System and the European EudraVigilance from week 52/2020 through week 31/2021 and compared them with those of other vaccines. Overall, 837,830,000 COVID-19 vaccine doses were delivered in the US and Europe during the study period, for which the vaccine name was known. The mean anaphylaxis rate was estimated at 10.67 cases per 10

Indexed as

AnaphylaxisCOVID-19COVID-19 VaccinesHumansInfantMeasles-Mumps-Rubella VaccineMumps VaccineSARS-CoV-2COVID-19 VaccinesMeasles-Mumps-Rubella VaccineMumps VaccineAllergyAnaphylaxisCOVID-19EudraVigilanceHypersensitivityVaccineVAERS

Identifiers

PMID34863620
PMCPMC8626274
OpenAlexW3215744219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.